Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in USPfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at Share XPfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in UShttps://pharmaphorum.com/news/pfizer-launches-biosimilars-to-roches-big-three-cancer-drugs-in-us/
Roche edges closer to SMA market as risdiplam hits target in trial in babiesRoche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the Share XRoche edges closer to SMA market as risdiplam hits target in trial in babieshttps://pharmaphorum.com/news/roche-sma-risdiplam-babies/
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from BayerThe UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share XTumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayerhttps://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
Roche and Illumina forge genomics alliance for cancer testingRoche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, Share XRoche and Illumina forge genomics alliance for cancer testinghttps://pharmaphorum.com/news/roche-and-illumina-forge-genomics-alliance-for-cancer-testing/
Ligelizumab could top Xolair in chronic hives, says NovartisNovartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XLigelizumab could top Xolair in chronic hives, says Novartishttps://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
Roche, big data and patient outcomes: the pharmaphorum podcastIn the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data Share XRoche, big data and patient outcomes: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/roche-big-data-and-patient-outcomes/
NICE rejects Roche’s Tecentriq in new lung cancer useNICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a Share XNICE rejects Roche’s Tecentriq in new lung cancer usehttps://pharmaphorum.com/news/nice-rejects-roches-tecentriq-in-new-lung-cancer-use/
Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
